[1] American Cancer Society. Breast Cancer Facts and Figures 2015-2016. Atlanta: American Cancer Society, Inc.
2015.
[2] Petrović, Nina. “miR-21 might be involved in breast cancer promotion and invasion rather than in initial events
of breast cancer development.” Molecular Diagnosis & Therapy Vol. 20, No. 2, 2016, pp. 97-110.
[3] Creighton, Chad J., Jenny C. Chang, and Jeffrey M. Rosen. “Epithelial-mesenchymal transition (EMT) in
tumor-initiating cells and its clinical implications in breast cancer.” Journal of Mammary Gland Biology and
Neoplasia Vol. 15, No. 2, 2010, pp. 253-60.
[4] Asangani, I. A., et al. “MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4
and stimulates invasion, intravasation and metastasis in colorectal cancer.” Oncogene Vol. 27, No. 15, 2008, pp.
2128-36.
[5] Hu, Jianzhong, et al. “The Angiogenic Effect of microRNA-21 Targeting TIMP3 through the Regulation of
MMP2 and MMP9.” PloS one Vol. 11, No. 2, 2016, p. e0149537.
[6] Gangoda, Lahiru, et al. “Extracellular vesicles including exosomes are mediators of signal transduction: are they
protective or pathogenic?” Proteomics Vol. 15, No. 2-3, 2015, pp. 260-71.
[7] Mitchell, Patrick S., et al. “Circulating microRNAs as stable blood-based markers for cancer detection.” Proceedings
of the National Academy of Sciences Vol. 105, No. 30, 2008, pp. 10513-18.
[8] Pritchard, Colin C., et al. “Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker
studies.” Cancer Prevention Research Vol. 5, No. 3, 2012, pp. 492-97.
Abdulhussain, et al. Int J Med Res Health Sci 2017, 6(12): 105-120
119
[9] Iorio, Marilena V., et al. “MicroRNA gene expression deregulation in human breast cancer.” Cancer Research Vol.
65, No. 16, 2005, pp. 7065-70.
[10] Wang, Kai, et al. “Comparing the MicroRNA spectrum between serum and plasma.” PloS one Vol. 7, No. 7,
2012, p. e41561.
[11] Livak, Kenneth J., and Thomas D. Schmittgen. “Analysis of relative gene expression data using real-time
quantitative PCR and the 2− ΔΔCT method.” Methods Vol. 25, No. 4, 2001, pp. 402-408.
[12] Kim, Hyoung Kyun, et al. “Expression of matrix metalloproteinase (MMP)-2, MMP-9, and tissue inhibitor of
MMP (TIMP)-1 in conjunctival melanomas and clinical implications.” Japanese Journal of Ophthalmology Vol.
54, No. 3, 2010, pp. 221-26.
[13] Van Roozendaal, Lori M., et al. “Risk of regional recurrence in triple-negative breast cancer patients: a Dutch
cohort study.” Breast Cancer Research and Treatment Vol. 156, No. 3, 2016, pp. 465-72.
[14] Akhtar, Murtaza, Subhrajit Dasgupta, and Murtuza Rangwala. “Triple negative breast cancer: an Indian
perspective.” Breast Cancer: Targets and Therapy Vol. 7, 2015, p. 239.
[15] Stover, Daniel G., and Eric P. Winer. “Tailoring adjuvant chemotherapy regimens for patients with triple negative
breast cancer.” The Breast Vol. 24, 2015, pp. S132-S135.
[16] Howlader, Nadia, et al. “US incidence of breast cancer subtypes defined by joint hormone receptor and HER2
status.” JNCI: Journal of the National Cancer Institute Vol. 106, No. 5, 2014.
[17] Fayaz, Mohammed S., et al. “Clinicopathological features and prognosis of triple negative breast cancer in
Kuwait: A comparative/perspective analysis.” Reports of Practical Oncology & Radiotherapy Vol. 19, No. 3,
2014, pp. 173-81.
[18] Williams, Zev, et al. “Comprehensive profiling of circulating microRNA via small RNA sequencing of cDNA
libraries reveals biomarker potential and limitations.” Proceedings of the National Academy of Sciences Vol. 110,
No. 11, 2013, pp. 4255-60.
[19] Schwarzenbach, Heidi, et al. “Clinical relevance of circulating cell-free microRNAs in cancer.” Nature Reviews
Clinical Oncology Vol. 11, No. 3, 2014, pp. 145-56.
[20] Hafez, Mohamed M., et al. “MicroRNAs and metastasis-related gene expression in Egyptian breast cancer
patients.” Asian Pacific Journal of Cancer Prevention Vol. 13, No. 2, 2012, pp. 591-98.
[21] Si, Haiyan, et al. “Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for
primary breast cancer.” Journal of Cancer Research and Clinical Oncology Vol. 139, No. 2, 2013, pp. 223-29.
[22] Heneghan, Helen M., et al. “Circulating microRNAs as novel minimally invasive biomarkers for breast
cancer.” Annals of Surgery Vol. 251, No. 3, 2010, pp. 499-505.
[23] Gao, Song, et al. “MicroRNA-155, induced by FOXP3 through transcriptional repression of BRCA1, is associated
with tumor initiation in human breast cancer.” Oncotarget Vol. 8, No. 25, 2017, p. 41451.
[24] Petrović, Nina, et al. “Higher miR-21 expression in invasive breast carcinomas is associated with positive estrogen and
progesterone receptor status in patients from Serbia.” Medical Oncology Vol. 31, No. 6, 2014, p. 977.
[25] Li, Jianyi, et al. “Genetic heterogeneity of breast cancer metastasis may be related to miR-21 regulation of TIMP-
3 in translation.” International Journal of Surgical Oncology Vol. 2013, 2013.
[26] Roth, Carina, et al. “Circulating microRNAs as blood-based markers for patients with primary and metastatic
breast cancer.” Breast Cancer Research Vol. 12, No. 6, 2010, p. R90.
[27] Han, Ji-Guang, et al. “A novel panel of serum miR-21/miR-155/miR-365 as a potential diagnostic biomarker for
breast cancer.” Annals of Surgical Treatment and Research Vol. 92, No. 2, 2017, pp. 55-66.
[28] Kong, William, et al. “MicroRNA-155 is regulated by the transforming growth factor β/Smad pathway and
contributes to epithelial cell plasticity by targeting RhoA.” Molecular and Cellular Biology Vol. 28, No. 22,
2008, pp. 6773-84.
[29] Hagrass, Hoda A., et al. “Circulating microRNAs-a new horizon in molecular diagnosis of breast cancer.” Genes
& Cancer Vol. 6, No. 5-6, 2015, p. 281.
[30] Elshimy, Reham AA, et al. “MiR-133a and MiR-155 as Potential Minimally Invasive Biomarkers in Breast
Cancer.” Cancer Biology Vol. 7, No. 1, 2017, pp. 96-105.
Abdulhussain, et al. Int J Med Res Health Sci 2017, 6(12): 105-120
120
[31] Criscitiello, Carmen, et al. “Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of
clinical use and molecular biomarkers for patient selection.” OncoTargets and Therapy Vol. 4, 2011, p. 1.
[32] Yan, Li-Xu, et al. “MicroRNA miR-21 overexpression in human breast cancer is associated with advanced
clinical stage, lymph node metastasis and patient poor prognosis.” Rna Vol. 14, No. 11, 2008, pp. 2348-60.
[33] Petrovic, Nina, Sercan Ergün, and Esma R. Isenovic. “Levels of MicroRNA Heterogeneity in Cancer
Biology.” Molecular Diagnosis & Therapy 2017, pp. 1-13.
[34] Zeng, Hui, et al. “The clinicopathological significance of microRNA-155 in breast cancer: a meta-analysis.” BioMed
Research International Vol. 2014, 2014.
[35] Petrović, Nina, et al. “miR-155 expression level changes might be associated with initial phases of breast cancer
pathogenesis and lymph-node metastasis.” Cancer Biomarkers Vol. 16, No. 3, 2016, pp. 385-94.
[36] Radojicic, Jelena, et al. “MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast
cancer.” Cell Cycle Vol. 10, No. 3, 2011, pp. 507-17.
[37] Thakur, Seema, et al. “Identification of Specific miRNA Signature in Paired Sera and Tissue Samples of Indian
Women with Triple Negative Breast Cancer.” PLoS one Vol. 11, No. 7, 2016, p. e0158946.
[38] Hanahan, Douglas, and Robert A. Weinberg. “Hallmarks of cancer: the next generation.” Cell Vol. 144, No. 5,
2011, pp. 646-74.
[39] Hippe A, Homey B, Mueller-Homey A. “Chemokines. Recent results in cancer research Fortschritte der
Krebsforschung” Progres dans les recherches sur le cancer Vol. 180, 2010, pp. 35-50.
[40] Serpico, Danila, Leonardo Molino, and Serena Di Cosimo. “microRNAs in breast cancer development and
treatment.” Cancer Treatment Reviews Vol. 40, No. 5, 2014, pp. 595-604.
[41] Yuan, Zhong-Yu, et al. “Overexpression of ETV4 protein in triple-negative breast cancer is associated with a
higher risk of distant metastasis.” OncoTargets and Therapy Vol. 7, 2014, p. 1733.
[42] Zonari, Erika, et al. “A role for miR-155 in enabling tumor-infiltrating innate immune cells to mount effective
anti-tumor responses.” Blood 2013.
[43] Kurozumi, Sasagu, et al. “Recent trends in microRNA research into breast cancer with particular focus on the
associations between microRNAs and intrinsic subtypes.” Journal of Human Genetics Vol. 62, No. 1, 2017, p. 15.
[44] Chang, Suhwan, and Shyam K. Sharan. “BRCA1 and microRNAs: emerging networks and potential therapeutic
targets.” Molecules and Cells 2012, pp. 1-8.
[45] Mylona, Eleni, et al. “Expression of tissue inhibitor of matrix metalloproteinases (TIMP)-3 protein in invasive
breast carcinoma: relation to tumor phenotype and clinical outcome.” Breast Cancer Research Vol. 8, No. 5,
2006, p. R57.
[46] Kotzsch, Matthias, et al. “Prognostic relevance of uPAR-del4/5 and TIMP-3 mRNA expression levels in breast
cancer.” European Journal of Cancer Vol. 41, No. 17, 2005, pp. 2760-68.
[47] Song, Bao, et al. “MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of
metalloproteinase 3 expression.” Journal of Experimental & Clinical Cancer Research Vol. 29, No. 1, 2010, p. 29.
[48] Dai, Jianwei, et al. “Andrographolide Inhibits Angiogenesis by Inhibiting the Mir-21-5p/TIMP3 Signaling
Pathway.” International Journal of Biological Sciences Vol. 13, No. 5, 2017, p. 660.
[49] Xu, Xialian, et al. “Renal Protection Mediated by Hypoxia Inducible Factor-1α Depends on Proangiogenesis
Function of miR-21 by Targeting Thrombospondin 1.” Transplantation Vol. 101, No. 8, 2017, p. 1811.
[50] Chen, Liang, et al. “Role of deregulated microRNAs in breast cancer progression using FFPE tissue.” PloS
one Vol. 8, No. 1, 2013, p. e54213.
[51] O’Bryan, Samia, et al. “The roles of oncogenic miRNAs and their therapeutic importance in breast
cancer.” European Journal of Cancer Vol. 72, 2017, pp. 1-11.
[52] Mishra, Sanjay, et al. “Circulating miRNAs revealed as surrogate molecular signatures for the early detection of
breast cancer.” Cancer Letters Vol. 369, No. 1, 2015, pp. 67-75.
Thank you for copying data from http://www.arastirmax.com
